Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis?

Best Practice and Research: Clinical Gastroenterology

Volumn 20, Issue 5, 2006, Pages 803-812

  Lagergren, Jesper ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

epidemiology; etiology; neoplasm; oesophagus; prevention

Indexed keywords

ACETYLSALICYLIC ACID; AMINOPHYLLINE; ANTIINFLAMMATORY AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; GLYCERYL TRINITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; STOMACH SECRETION INHIBITOR;

ANTIREFLUX OPERATION; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; CANCER INCIDENCE; CANCER MORTALITY; CARCINOGENESIS; CAUCASIAN; CHEMOPROPHYLAXIS; CIGARETTE SMOKING; DISEASE ASSOCIATION; DRUG INDICATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS SURGERY; FOOD INTAKE; FRUIT; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INDUSTRIALIZATION; LIPID DIET; LOWER ESOPHAGUS SPHINCTER; METHODOLOGY; NUTRIENT CONTENT; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; VEGETABLE;

ADENOCARCINOMA; AGE FACTORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BARRETT ESOPHAGUS; BODY MASS INDEX; CHEMOPREVENTION; ESOPHAGEAL NEOPLASMS; ESOPHAGEAL SPHINCTER, LOWER; FOOD HABITS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; PROGNOSIS; RISK FACTORS; SMOKING;

EID: 33748684348     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2006.04.009     Document Type: Article

References (69)

1. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
2. Bollschweiler E., Wolfgarten E., Gutschow C., et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92 (2001) 549-555
3. Hansson L.E., Sparen P., and Nyren O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer 54 (1993) 402-407
4. Botterweck A.A., Schouten L.J., Volovics A., et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29 (2000) 645-654
5. Corley D.A., and Buffler P.A. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 30 (2001) 1415-1425
6. Hansson L.E., Sparen P., and Nyren O. Increasing incidence of carcinoma of the gastric cardia in Sweden from 1970 to 1985. Br J Surg 80 (1993) 374-377
7. Lindblad M., Lindgren A., Ye W., et al. Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates. Ann Surg 243 (2006) 479-485
8. Pohl H., and Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97 (2005) 142-146
9. El-Serag H.B., and Sonnenberg A. Ethnic variations in the occurrence of gastroesophageal cancers. J Clin Gastroenterol 28 (1999) 135-139
10. Cheng K.K., Sharp L., McKinney P.A., et al. A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer 83 (2000) 127-132
11. Lagergren J., and Nyren O. Do sex hormones play a role in the etiology of esophageal adenocarcinoma? A new hypothesis tested in a population-based cohort of prostate cancer patients. Cancer Epidemiol Biomarkers Prev 7 (1998) 913-915
12. Lindblad M., García Rodríguez L., Chandanos E., et al. Hormone replacement therapy and risk of oesophageal and gastric adenocarcinoma. Br J Cancer 94 (2006) 136-141
13. Lagergren J., and Jansson C. Sex hormones and oesophageal adenocarcinoma: influence of childbearing?. Br J Cancer 93 (2005) 859-861
14. Spechler S.J., and Goyal R.K. Barrett's esophagus. N Engl J Med 315 (1986) 362-371
15. Pera M., Manterola C., Vidal O., et al. Epidemiology of esophageal adenocarcinoma. J Surg Oncol 92 (2005) 151-159
16. Sharma P., and Sidorenko E.I. Are screening and surveillance for Barrett's oesophagus really worthwhile?. Gut 54 supplement 1 (2005) i27-i32
17. Dellon E.S., and Shaheen N.J. Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival?. J Clin Oncol 23 (2005) 4478-4482
18. Chow W.H., Finkle W.D., McLaughlin J.K., et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 274 (1995) 474-477
19. Lagergren J., Bergstrom R., Lindgren A., et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340 (1999) 825-831
20. Farrow D.C., Vaughan T.L., Sweeney C., et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 11 (2000) 231-238
21. Wu A.H., Tseng C.C., and Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 98 (2003) 940-948
22. Ye W., Chow W.H., Lagergren J., et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 121 (2001) 1286-1293
23. Lagergren J., Ye W., Bergstrom R., et al. Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. JAMA 284 (2000) 961-962
24. Inadomi J., Sampliner R., Lagergren J., et al. Screening and surveillance for Barrett's esophagus in high-risk patients: a cost-utility analysis. Ann Intern Med 138 (2003) 176-186
25. Lagergren J., Bergstrom R., Adami H.O., et al. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 133 (2000) 165-175
26. Vaughan T.L., Farrow D.C., Hansten P.D., et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 7 (1998) 749-756
27. Spechler S.J., Lee E., Ahnen D., et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 285 (2001) 2331-2338
28. Fitzgerald R.C., Omary M.B., and Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 98 (1996) 2120-2128
29. Ouatu-Lascar R., Fitzgerald R.C., and Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 117 (1999) 327-335
30. Csendes A., Burdiles P., Braghetto I., et al. Adenocarcinoma appearing very late after antireflux surgery for Barrett's esophagus: long-term follow-up, review of the literature, and addition of six patients. J Gastrointest Surg 8 (2004) 434-441
31. Chow W.H., Blot W.J., Vaughan T.L., et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 90 (1998) 150-155
32. Lagergren J., Bergstrom R., and Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 130 (1999) 883-890
33. Lindblad M., Rodriguez L.A., and Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study. Cancer Causes Control 16 (2005) 285-294
34. Locke III G.R., Talley N.J., Fett S.L., et al. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 106 (1999) 642-649
35. Nilsson M., Johnsen R., Ye W., et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 290 (2003) 66-72
36. Seidell J.C. Time trends in obesity: an epidemiological perspective. Horm Metab Res 29 (1997) 155-158
37. Seidell J.C. Prevalence and time trends of obesity in Europe. J Endocrinol Invest 25 (2002) 816-822
38. Gammon M.D., Schoenberg J.B., Ahsan H., et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 89 (1997) 1277-1284
39. Lagergren J., Bergstrom R., Lindgren A., et al. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 85 (2000) 340-346
40. Wu A.H., Wan P., and Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 12 (2001) 721-732
41. Edwards B.K., Brown M.L., Wingo P.A., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97 (2005) 1407-1427
42. Gronbaek M., Becker U., Johansen D., et al. Population based cohort study of the association between alcohol intake and cancer of the upper digestive tract. BMJ 317 (1998) 844-847
43. Chow W.H., Blaser M.J., Blot W.J., et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 58 (1998) 588-590
44. Wu A.H., Crabtree J.E., Bernstein L., et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 103 (2003) 815-821
45. Ye W., Held M., Lagergren J., et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 96 (2004) 388-396
46. Asano T.K., and McLeod R.S. Non-steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev (2004) CD004079
47. Corley D.A., Kerlikowske K., Verma R., et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124 (2003) 47-56
48. Gonzalez-Perez A., Garcia Rodriguez L.A., and Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 3 (2003) 28
49. Salas M., Hofman A., and Stricker B.H. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 149 (1999) 981-983
50. Signorello L.B., McLaughlin J.K., Lipworth L., et al. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther 9 (2002) 199-205
51. Lindblad M., Lagergren J., and Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 444-450
52. Tuynman J.B., Buskens C.J., Kemper K., et al. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg 242 (2005) 840-849 [discussion 849-850]
53. Mayne S.T., and Navarro S.A. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr 132 (2002) 3467S-3470S
54. Wong A., and Fitzgerald R.C. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 3 (2005) 1-10
55. Terry P., Lagergren J., Ye W., et al. Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer 87 (2000) 750-754
56. Chen H., Tucker K.L., Graubard B.I., et al. Nutrient intakes and adenocarcinoma of the esophagus and distal stomach. Nutr Cancer 42 (2002) 33-40
57. McColl K.E. When saliva meets acid: chemical warfare at the oesophagogastric junction. Gut 54 (2005) 1-3
58. Suzuki H., Iijima K., Scobie G., et al. Nitrate and nitrosative chemistry within Barrett's oesophagus during acid reflux. Gut 54 (2005) 1527-1535
59. Terry P., Lagergren J., Wolk A., et al. Reflux-inducing dietary factors and risk of adenocarcinoma of the esophagus and gastric cardia. Nutr Cancer 38 (2000) 186-191
60. Terry P., Lagergren J., Wolk A., et al. Drinking hot beverages is not associated with risk of oesophageal cancers in a Western population. Br J Cancer 84 (2001) 120-121
61. Berrino F., World Health Organization, International Agency for Research on Cancer, and Commission of the European Communities. Survival of Cancer Patients in Europe: The EUROCARE-2 Study. IARC scientific publications no. 151 (1999), International Agency for Research on Cancer, Lyon
62. Sundelof M., Ye W., Dickman P.W., et al. Improved survival in both histologic types of oesophageal cancer in Sweden. Int J Cancer 99 (2002) 751-754
63. Eloubeidi M.A., Mason A.C., Desmond R.A., et al. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?. Am J Gastroenterol 98 (2003) 1627-1633
64. Enzinger P.C., and Mayer R.J. Esophageal cancer. N Engl J Med 349 (2003) 2241-2252
65. Wu P.C., and Posner M.C. The role of surgery in the management of oesophageal cancer. Lancet Oncol 4 (2003) 481-488
66. Stein H.J., and Siewert J.R. Improved prognosis of resected esophageal cancer. World J Surg 28 (2004) 520-525
67. Rouvelas I., Zeng W., Lindblad M., et al. Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol 6 (2005) 864-870
68. Law S., Kwong D.L., Kwok K.F., et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg 238 (2003) 339-347 [discussion 347-348]
69. Casson A.G., and van Lanschot J.J. Improving outcomes after esophagectomy: the impact of operative volume. J Surg Oncol 92 (2005) 262-266